Asthma Severity Classification (GINA)
GINA (Global Initiative for Asthma) 2023 severity and control classification. Guides step-up/step-down of inhaled therapy from Step 1 (PRN SABA) to Step 5 (biologic therapy).
Score interpretation
→ GINA Well-Controlled: Good control. Step down if on Step 3+; continue current treatment. PRN low-dose ICS-formoterol if on Step 1; review adherence, inhaler technique, and triggers at each visit.
→ GINA Partly Controlled: 1–2 areas uncontrolled. Consider step-up (one GINA step); review inhaler technique and adherence; check trigger avoidance; add LABA if Step 2; increase ICS dose if Step 3. Review in 4–6 weeks.
→ GINA Uncontrolled: ≥3 areas uncontrolled. Step up immediately. If Step 4–5: add biologic (dupilumab, mepolizumab, omalizumab per phenotype); refer to respiratory specialist; consider oral corticosteroid short course; urgent review; exclude alternative diagnoses (VCD, EGPA).
Interpretation bands for the GINA Asthma Severity. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Fluticasone Furoate / Vilanterol · ICS/LABA — Asthma / COPD
- Beclometasone / Formoterol · ICS/LABA — Asthma / COPD
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Tezepelumab (CRSwNP / Severe Asthma) · Anti-TSLP (Thymic Stromal Lymphopoietin) Monoclonal Antibody
- Morphine (Oral) · Strong Opioid Analgesic — Step 3 WHO Ladder
- Oxycodone · Strong Opioid Analgesic — Step 3 WHO Ladder
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.